Talk:BNC-210

Updated the article with 2 press releases and 1 journal article. Very little info on the IND exist. By far the best source is the recent (May 2020) paper https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198974/ here. I got side tracked updating this, and have something else I should be doing. I invite others to add to it. I suppose there may be renewed interest in this if it gets to phase III. I am skeptical this drug will have an efficatious enough response to move forward. But then we have other things out there with limited efficacy, and anything that isn't a Benzodiazepine or SSRI and can be used in tanget with these has a shot at getting through (See Buspirone). I have no relationship to the company, the research, the drugs herein. I do have a bg in Pharmaceutical Chemistry and Medicine. But not anything in this area. I remain fascinated by brain chem, but generally work elsewhere. --Gizmo.AT (talk) 02:02, 10 September 2020 (UTC)

Biol Psychiatry. 2020 May 15; 87(10): 908–915. doi: 10.1016/j.biopsych.2019.12.013 PMCID: PMC7198974 PMID: 32107005 Cholinergic Modulation of Disorder-Relevant Neural Circuits in Generalized Anxiety Disorder Toby Wise,a,d,e,h,1,∗ Fiona Patrick,a,b,1 Nicholas Meyer,c Ndaba Mazibuko,b Alice E. Oates,g Anne H.M. van der Bijl,i Philippe Danjou,j Susan M. O’Connor,k Elizabeth Doolin,k Caroline Wooldridge,b Deborah Rathjen,l Christine Macare,a Steven C.R. Williams,b,f Adam Perkins,2,a,f and Allan H. Younga,f,2 — Preceding unsigned comment added by Gizmo.AT (talk • contribs) 01:40, 10 September 2020 (UTC)

I added a note at the end of the mechanism, referring to conclusions on the effects of the drug. While this is speculation and does not typically belong here, I also know that people comb the INDs out there looking for new designer drugs, and we don't need people cooking this up. If they're going to make something in their basement, it might as well be something good. --Gizmo.AT (talk) 02:02, 10 September 2020 (UTC)